ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions
View by Date
  • Abstract Number: 1800

    A Declining Trend in Frequency of Secondary Amyloidosis in Behçet’s Syndrome
  • Abstract Number: 1801

    Factors Associated with Damage Progression in Behçet’s Syndrome Uveitis
  • Abstract Number: 1802

    Behcet’s Disease in the Southwestern United States
  • Abstract Number: 1803

    Assessment of Severity and Risk Factors of Post-Thrombotic Syndrome in Vascular Behçet Disease: Muticentered Retrospective Study
  • Abstract Number: 1804

    Optimization Protocol for Adalimumab Treatment in Refractory Uveitis Due to Behçet’s Disease
  • Abstract Number: 1805

    Strong Association of HLA-DRB1*0901 with Japanese Patients with Chronic Progressive Neuro-Behçet’s Disease
  • Abstract Number: 1806

    Spinal Cord Involvement in Behcet’s Disease- Experience of a Vasculitis Centre at Silk Road
  • Abstract Number: 1807

    Clinical Features and Disease Course of Neurologic Involvement in Behcet’s Disease
  • Abstract Number: 1808

    Increased Frequency of Obstructive Sleep Apnea Syndrome in Behcet’s Syndrome Patients with Vena Cava Superior Thrombosis
  • Abstract Number: 1809

    Clinical Characteristics of Older Age-Onset Behçet Syndrome Patients
  • Abstract Number: 1810

    Initial Visit Symptoms in Probable Behçet’s Predictive of ISG Criteria Behçet’s: Data from New York and Amsterdam Cohorts
  • Abstract Number: 1811

    Efficacy and Safety of Interferon α2a As an Add-on Treatment for Refractory Behcet’s Uveitis
  • Abstract Number: 1812

    Characterization and Prevalence of Morbus Behçet in Switzerland
  • Abstract Number: 1813

    Non-Aphthous Beginning As an Independent Risk Factor for the Course of Behçet’s Disease
  • Abstract Number: 1814

    Interferon-Alpha for the Management of Lower Extremity Deep Vein Thrombosis in Behcet’s Syndrome: A Case Series
  • « Previous Page
  • 1
  • …
  • 121
  • 122
  • 123
  • 124
  • 125
  • …
  • 202
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology